Phase II trials further reported that MK-2206 restores erlotinib activity in patients with advanced non-small cell lung cancer (NSCLC) and improves the response to paclitaxel and trastuzumab in patients with hormone receptor (HR)-negative and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [23, 24]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.